Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

India is emerging as an economic superpower, highlighted David Ricks, CEO, Eli Lilly, a pharmaceutical company, following a ...